[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
We observed the effects of intravesical irrigation with BCG (group B), Mitomycin-C (group M), and Thiotepa (group T) in prophylaxis of bladder tumor recurrence after surgical treatment. Follow-up for 1-10 years showed that the recurrence rate of bladder tumor was 12.5% (3/24) in group B, 46.9% (15/33) in group M, and 61.8% (21/34) in group T respectively. The effect of BCG was far better than that Mitomycin-C and Thiotepa (P < 0.01). In 5 cases, who failed to Thiotepa, also showed satisfactory results after use of intravesical BCG. Considering the side-effects of intravesical BCG, Thiotepa or Mitomycin-C should be used as the first choice of drugs in preventing the tumor recurrence.
Wang
S H
SH
Beijing Hospital.
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011184:Postoperative Period; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control* / Q000601:surgery
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin; D013852:Thiotepa